 | • レポートコード：MRC2211A077 • 出版社/出版日：Transparency Market Research / 2022年8月 • レポート形態：英文、PDF、176ページ • 納品方法：Eメール • 産業分類：バイオ |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界のレッドバイオテクノロジー市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、用途別（バイオ医薬品製造、遺伝子治療、ファーマコゲノミクス、遺伝子検査）分析、エンドユーザー別（バイオ医薬品産業、CMO＆CRO、研究機関、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を掲載しています。なお、当書には、Pfizer, Inc.、Biogen, Inc.、Amgen, Inc.、AstraZeneca plc、Gilead Sciences, Inc.、Celgene Corporation (Bristol-Myers Squibb Company)、F. Hoffmann-La Roche, Ltd.、Merck KGaA、Regeneron Pharmaceuticals, Inc.、Takeda Pharmaceutical Company Limitedなどの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のレッドバイオテクノロジー市場規模：用途別 - バイオ医薬品製造における市場規模 - 遺伝子治療における市場規模 - ファーマコゲノミクスにおける市場規模 - 遺伝子検査における市場規模 ・世界のレッドバイオテクノロジー市場規模：エンドユーザー別 - バイオ医薬品産業における市場規模 - CMO＆CROにおける市場規模 - 研究機関における市場規模 - その他エンドユーザーにおける市場規模 ・世界のレッドバイオテクノロジー市場規模：地域別 - 北米のレッドバイオテクノロジー市場規模 - ヨーロッパのレッドバイオテクノロジー市場規模 - アジア太平洋のレッドバイオテクノロジー市場規模 - 中南米のレッドバイオテクノロジー市場規模 - 中東・アフリカのレッドバイオテクノロジー市場規模 ・競争状況 |
Red Biotechnology Market – Scope of Report
TMR’s report on the global red biotechnology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global red biotechnology market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global red biotechnology market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the red biotechnology market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global red biotechnology market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global red biotechnology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global red biotechnology market.
The report delves into the competitive landscape of the global red biotechnology market. Key players operating in the global red biotechnology market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global red biotechnology market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market red biotechnology.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Red Biotechnology Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Red Biotechnology Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Reimbursement Scenario by Region/globally
5.3. Key Industry Events (merger & acquisitions)
5.4. Covid-19 Impact Analysis
6. Global Red Biotechnology Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Application, 2017–2031
6.3.1. Biopharmaceutical Production
6.3.2. Pharmacogenomics
6.3.3. Gene Therapy
6.3.4. Genetic Testing
6.4. Market Attractiveness Analysis, by Application
7. Global Red Biotechnology Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Biopharmaceutical Industry
7.3.2. CMO & CRO
7.3.3. Research Institutes
7.3.4. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global Red Biotechnology Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Red Biotechnology Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Application, 2017–2031
9.2.1. Biopharmaceutical Production
9.2.2. Pharmacogenomics
9.2.3. Gene Therapy
9.2.4. Genetic Testing
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Biopharmaceutical Industry
9.3.2. CMO & CRO
9.3.3. Research Institutes
9.3.4. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Application
9.5.2. By End-user
9.5.3. By Country
10. Europe Red Biotechnology Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Application, 2017–2031
10.2.1. Biopharmaceutical Production
10.2.2. Pharmacogenomics
10.2.3. Gene Therapy
10.2.4. Genetic Testing
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Biopharmaceutical Industry
10.3.2. CMO & CRO
10.3.3. Research Institutes
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Application
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Red Biotechnology Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Application, 2017–2031
11.2.1. Biopharmaceutical Production
11.2.2. Pharmacogenomics
11.2.3. Gene Therapy
11.2.4. Genetic Testing
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Biopharmaceutical Industry
11.3.2. CMO & CRO
11.3.3. Research Institutes
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Application
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Red Biotechnology Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Application, 2017–2031
12.2.1. Biopharmaceutical Production
12.2.2. Pharmacogenomics
12.2.3. Gene Therapy
12.2.4. Genetic Testing
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Biopharmaceutical Industry
12.3.2. CMO & CRO
12.3.3. Research Institutes
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Application
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Red Biotechnology Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Application, 2017–2031
13.2.1. Biopharmaceutical Production
13.2.2. Pharmacogenomics
13.2.3. Gene Therapy
13.2.4. Genetic Testing
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Biopharmaceutical Industry
13.3.2. CMO & CRO
13.3.3. Research Institutes
13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Application
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. Business Strategies
14.3.1.5. Recent Developments
14.3.2. Biogen, Inc.
14.3.2.1. Company Overview
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. Business Strategies
14.3.2.5. Recent Developments
14.3.3. Amgen, Inc.
14.3.3.1. Company Overview
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. Business Strategies
14.3.3.5. Recent Developments
14.3.4. AstraZeneca plc
14.3.4.1. Company Overview
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. Business Strategies
14.3.4.5. Recent Developments
14.3.5. Gilead Sciences, Inc.
14.3.5.1. Company Overview
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. Business Strategies
14.3.5.5. Recent Developments
14.3.6. Celgene Corporation (Bristol-Myers Squibb Company)
14.3.6.1. Company Overview
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. Business Strategies
14.3.6.5. Recent Developments
14.3.7. F. Hoffmann-La Roche, Ltd.
14.3.7.1. Company Overview
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. Business Strategies
14.3.7.5. Recent Developments
14.3.8. Merck KGaA
14.3.8.1. Company Overview
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. Business Strategies
14.3.8.5. Recent Developments
14.3.9. Regeneron Pharmaceuticals, Inc.
14.3.9.1. Company Overview
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. Business Strategies
14.3.9.5. Recent Developments
14.3.10. Takeda Pharmaceutical Company Limited
14.3.10.1. Company Overview
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. Business Strategies
14.3.10.5. Recent Developments
Table 01: Global Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031
Table 02: Global Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 03: Global Red Biotechnology Market Value (US$ Bn) Forecast, by Region, 2022–2031
Table 04: North America Red Biotechnology Market Value (US$ Bn) Forecast, by Country, 2022–2031
Table 05: North America Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031
Table 06: North America Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 07: Europe Red Biotechnology Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 08: Europe Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031
Table 09: Europe Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 10: Asia Pacific Red Biotechnology Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 11: Asia Pacific Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031
Table 12: Asia Pacific Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 13: Latin America Red Biotechnology Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 14: Latin America Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031
Table 15: Latin America Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 16: Middle East & Africa Red Biotechnology Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 17: Middle East & Africa Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2022–2031
Table 18: Middle East & Africa Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2022–2031